KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Accumulated Expenses: 2010-2019

Historic Accumulated Expenses for Biomarin Pharmaceutical (BMRN) over the last 8 years, with Mar 2019 value amounting to $87.3 million.

  • Biomarin Pharmaceutical's Accumulated Expenses rose 13.92% to $87.3 million in Q1 2019 from the same period last year, while for Mar 2019 it was $87.3 million, marking a year-over-year increase of 13.92%. This contributed to the annual value of $149.9 million for FY2018, which is 6.50% up from last year.
  • Biomarin Pharmaceutical's Accumulated Expenses amounted to $87.3 million in Q1 2019, which was down 41.80% from $149.9 million recorded in Q4 2018.
  • Over the past 5 years, Biomarin Pharmaceutical's Accumulated Expenses peaked at $149.9 million during Q4 2018, and registered a low of $45.0 million during Q1 2016.
  • Its 3-year average for Accumulated Expenses is $100.6 million, with a median of $95.0 million in 2018.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 109.65% in 2015, then tumbled by 57.70% in 2016.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Accumulated Expenses stood at $95.3 million in 2015, then rose by 14.36% to $109.0 million in 2016, then grew by 29.11% to $140.8 million in 2017, then climbed by 6.50% to $149.9 million in 2018, then increased by 13.92% to $87.3 million in 2019.
  • Its last three reported values are $87.3 million in Q1 2019, $149.9 million for Q4 2018, and $114.5 million during Q3 2018.